DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)

Journal of the National Cancer Institute

Volumn 106, Issue 12, 2014, Pages

  Lee, Adam M ^a   Shi, Qian ^a   Pavey, Emily ^a   Alberts, Steven R ^a   Sargent, Daniel J ^a   Sinicrope, Frank A ^a   Berenberg, Jeffrey L ^b   Goldberg, Richard M ^c   Diasio, Robert B ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; ASPARTIC ACID; CAMPTOTHECIN; PLATINUM COMPLEX; VALINE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; COLON CANCER; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PAIN; PHASE 3 CLINICAL TRIAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; CANCER STAGING; CHEMICALLY INDUCED; COLONIC NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DIARRHEA; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUOROURACIL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUCOVORIN; LOGISTIC MODELS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA; VALINE; VOMITING;

EID: 84961288145     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju298     Document Type: Article

References (40)

1. de Gramont A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-2947.
2. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated metaanalysis. J Clin Oncol. 2004;22(18):3766-3775.
3. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-1417.
4. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30.
5. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16:215-237.
6. McLeod HL, Papageorgio C, Watters JW. Using genetic variation to optimize cancer chemotherapy. Clin Adv Hematol Oncol. 2003;1(2):107-111.
7. Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, Van Gennip AH, Gonzalez FJ. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol. 1995;14(1):1-6.
8. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996;98(3):610-615.
9. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res. 2002;8(3):768-774.
10. Van Kuilenburg AB, Vreken P, Beex LV, et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer. 1997;33(13):2258-2264.
11. Van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705-4712.
12. Van Kuilenburg AB, Dobritzsch D, Meinsma R, et al. Novel diseasecausing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three dimensional protein structure. Biochem J. 2002;364:157-163.
13. Mattison LK, Johnson MR, Diasio RB. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA, conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics. 2002;12(2):133-144.
14. Seck K, Riemer S, Kates R, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res. 2005;11(16):5866-5892.
15. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using realtime cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 2013;73(6):1958-1968.
16. Offer SM, Fossum CC, Wegner NJ, Stufflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74(9):2545-2554.
17. Boisdron-Celle M, Remaud G, Traore S, et al. 5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 2007;249(2):271-282.
18. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5(11):2895-2904.
19. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin Oncol. 2008;26(13):2131-2138.
20. Gross E, Busse B, Riemenschneider M, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One. 2008;3(12):e4003.
21. Collie-Duguid ES, Etienne MC, Milano G, Mcleod HI. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 2000;10(3):217-223.
22. Ridge SA, Sludden J, Brown O, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol. 1998;46(2): 151-156.
23. Braun MS, Richman SD, Thompson L, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol. 2009;27(33):5519-5528.
24. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. (dbSNP Build ID: human 138). Available at: http://www.ncbi. nlm.nih.gov/projects/SNP/snp-ref.cgi?showRare=on&chooseRs=coding &go=Go&locusId=1806. Accessed February 6, 2013.
25. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307:1383-1393.
26. Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;10;31(29):3664-3672.
27. Altman DG. "Practical Statistics for Medical Research." London: Chapman & Hall, 1991.
28. th edition. Pacific Grove, CA: Duxbury, 2000.
29. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457-481.
30. Cox DR. Regression Models and Life-Tables. J Royal Stat Soc. Series B (Methodological). 1972;34(2):187-220.
31. Table of US FDA-approved pharmacogenomic biomarkers in drug labels. Available at: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed January 14, 2014.
32. Loganayagam A, Arenas-Hernandez M, Fairbanks L, Ross P, Sanderson JD, Marinaki A. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer Chemother Pharmacol. 2010;65(2):403-406.
33. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Lifethreatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5(8):2006-2011.
34. Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res. 2003;9(8):3021-3028.
35. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other 5-fluorouracil-based regimens: investigation in the QUASAR2 study, systemic review and meta-analysis. J Clin Oncol. 2014;32(10):1031-1039.
36. Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics. 2013;14(11):1255-1272.
37. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103(6):1165-1171.
38. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with Fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20(6):1491-1498.
39. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing. Clin Pharmacol Ther. 2013;94(6):640-645.
40. Vreken P, Van Kuilenburg AB, Meinsma R, van Gennip AH. Dihydropyrimidine dehydrogenase deficiency: identification and expression of missense mutations C29R, R886H, and R235W. Hum Genet. 1997;101(3):333-338.